Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VAX181
- Development stage
- Unknown
- Lead developer
- Vaxent
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Intramuscular
01
Overview
VAX181 is a recombinant influenza vaccine component developed by Vaxent intended to provide immunity against influenza. It is not available as a standalone drug, but is mixed ("field mix") with other components such as VAX128C, VAX173, and VAX172 to create a quadrivalent recombinant influenza vaccine (VAX2012Q). The vaccine is designed to stimulate an immune response via exposure to recombinant antigens that mimic the influenza virus, thereby preparing the immune system to recognize and fight real influenza infection[6].
- Brand names
- VAX181VAX-181VAX 181
- Other names
- VAX181VAX-181VAX 181
02
Targets
TLR5
Beyond the preview
Go deeper on VAX181.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VAX181.